Loading…
CEL-SCI Corporation is projected to rise to $1.87 by 2027, a +33% move from its current price of $1.41. CVM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.30 | $1.41 | $1.53 | -0.10% |
| May 30 | $1.25 | $1.41 | $1.58 | -0.19% |
| May 31 | $1.22 | $1.41 | $1.63 | -0.29% |
| Jun 1 | $1.19 | $1.40 | $1.66 | -0.39% |
| Jun 2 | $1.16 | $1.40 | $1.69 | -0.48% |
| Jun 3 | $1.14 | $1.40 | $1.72 | -0.58% |
| Jun 4 | $1.12 | $1.40 | $1.75 | -0.67% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.12 | $1.40 | $1.75 | -0.67% |
| Week 2 | $1.02 | $1.39 | $1.90 | -1.34% |
| Week 3 | $0.9411 | $1.38 | $2.03 | -2.01% |
| Week 4 | $0.8809 | $1.37 | $2.14 | -2.67% |
| Week 5 | $0.8303 | $1.36 | $2.24 | -3.33% |
| Week 6 | $0.7866 | $1.35 | $2.33 | -3.98% |
| Week 7 | $0.7481 | $1.34 | $2.42 | -4.62% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CEL-SCI Corporation is a clinical-stage biotechnology company focused on cancer and immune-system–based therapies in the United States. Its lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
The company also develops LEAPS technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. The LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer.
The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
CEL-SCI Corporation (CVM) is a healthcare stock. The current price is $1.42 and the market capitalization is $20.58M. It ranks 4930 by market capitalization.
The 30-day technical picture shows neutral sentiment with RSI14 at 30, and the stock trades below its SMA50 ($3.00) and SMA200 ($6.09). The current price sits between support at $1.19 and resistance at $4.95, with a 30-day price range from $0.7893 to $2.55.
Forecast snapshots indicate a year-by-year path: 2026 avg $1.42; 2027 avg $1.87; 2028 avg $1.99; 2029 avg $1.74; 2030 avg $1.53; 2040 avg $3.01; 2050 avg $4.80. Forecast max values reach as high as $11.03 in 2050, with notable bull and neutral periods reflected in the sentiment indicators for various years.
Overall, the outlook shows a mix of neutral and bullish phases over the longer horizon, with potential upside reflected in later years while acknowledging the inherent uncertainty of stock forecasting.
A major floor 15.6% below — a decisive break under it would weaken the trend.
The nearest floor, 15.6% below — buyers have tended to step in here.
The nearest ceiling, 251.1% above — a clean break opens room to run.
A major ceiling 361.7% above — clearing it would confirm fresh momentum.
Key CVM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CVM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.46 | Sell | $1.45 | Sell |
| MA 10 | $1.45 | Sell | $1.52 | Sell |
| MA 20 | $1.68 | Sell | $1.84 | Sell |
| MA 50 | $2.91 | Sell | $2.71 | Sell |
| MA 100 | $3.92 | Sell | $3.75 | Sell |
| MA 200 | $6.03 | Sell | $5.77 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.77 | Neutral |
| Stoch RSI (14) | 67.94 | Neutral |
| CCI (20) | -53.42 | Neutral |
| Williams %R (14) | -58.49 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | -17.06 | Sell |
| Bollinger %B (20,2) | 0.36 | Neutral |
| Stochastic %K (14) | 41.51 | Neutral |
| TRIX (15) | -2.91 | Sell |
| Awesome (5,34) | -1.13 | Sell |
| Ultimate (7,14,28) | 44.86 | Neutral |
| Momentum (10) | 0.22 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 1.40 | Buy |
| ADX (14) | 32.91 | Sell |
| ATR (14) | 0.16 | Info |
The 30-day technical picture is neutral, with RSI14 at 30. The stock is trading below both the SMA50 ($3.00) and the SMA200 ($6.09).
Prices are between a defined support of $1.19 and a resistance of $4.95, while the 30-day range spans from a low of $0.7893 to a high of $2.55.
Annualized volatility sits at 200%, indicating a high level of short-term risk for this name.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.19 | $1.41 | $2.36 | 0% | Neutral | |
| $1.35 | $1.87 | $2.82 | +33% | Bullish | |
| $1.33 | $1.96 | $3.14 | +39% | Bullish | |
| $1.11 | $1.73 | $2.90 | +23% | Bullish | |
| $0.9423 | $1.53 | $2.67 | +9% | Neutral | |
| $0.9801 | $1.67 | $3.00 | +18% | Neutral | |
| $1.03 | $1.83 | $3.40 | +30% | Bullish | |
| $1.23 | $2.27 | $4.34 | +61% | Bullish | |
| $1.27 | $2.44 | $4.77 | +73% | Bullish | |
| $1.13 | $2.26 | $4.53 | +60% | Bullish | |
| $1.33 | $2.96 | $6.51 | +110% | Bullish | |
| $2.14 | $4.75 | $10.93 | +237% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.19 | $1.41 | $1.67 | +0.00% |
| June 2026 | $1.08 | $1.30 | $1.61 | -8.06% |
| July 2026 | $1.06 | $1.29 | $1.65 | -0.41% |
| August 2026 | $1.13 | $1.40 | $1.82 | +8.37% |
| September 2026 | $1.12 | $1.40 | $1.85 | +0.13% |
| October 2026 | $1.10 | $1.39 | $1.86 | -0.55% |
| November 2026 | $1.22 | $1.56 | $2.11 | +11.75% |
| December 2026 | $1.34 | $1.72 | $2.36 | +10.53% |
Click any year to see its month-by-month CVM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CVM is projected to trade between $1.19 and $2.36, averaging $1.41 — a potential gain of 0% from today's $1.41. A consolidation phase looks the most probable path here.
CEL-SCI Corporation's 2027 outlook centres on $1.87, within a $1.35 to $2.82 range. That is up +33% on the projected 2026 average. That marks a +33% change versus current levels. Momentum favours further upside here.
By 2028, CVM could reach as high as $3.14, with a base case around $1.96 and support toward $1.33 — roughly +39% from $1.41. Buyers look set to stay in control over this stretch.
Expect CVM to range from $1.11 to $2.90 through 2029. The $1.73 average target implies a +23% move from current prices. That is -12% versus the projected 2028 average. Momentum favours further upside here.
The CVM price prediction for 2030 points to an average of $1.53 (low $0.9423, high $2.67) — a potential gain of +9% on today's $1.41. A consolidation phase looks the most probable path here.
In 2031, CVM is projected to trade between $0.9801 and $3.00, averaging $1.67 — a potential gain of +18% from today's $1.41. That is up +9% on the projected 2030 average. Price action looks broadly range-bound.
CEL-SCI Corporation's 2032 outlook centres on $1.83, within a $1.03 to $3.40 range. That is up +10% on the projected 2031 average. That marks a +30% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CVM could reach as high as $4.34, with a base case around $2.27 and support toward $1.23 — roughly +61% from $1.41. Momentum favours further upside here.
Expect CVM to range from $1.27 to $4.77 through 2034. The $2.44 average target implies a +73% move from current prices. That is up +7% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The CVM price prediction for 2035 points to an average of $2.26 (low $1.13, high $4.53) — a potential gain of +60% on today's $1.41. Momentum favours further upside here.
In 2040, CVM is projected to trade between $1.33 and $6.51, averaging $2.96 — a potential gain of +110% from today's $1.41. That is up +31% on the projected 2035 average. Buyers look set to stay in control over this stretch.
CEL-SCI Corporation's 2050 outlook centres on $4.75, within a $2.14 to $10.93 range. That is up +61% on the projected 2040 average. That marks a +237% change versus current levels. Momentum favours further upside here.
Investing $1,000 in CVM today (≈ 709.219858 CVM) could be worth
$3,371.27
+$2,371.27 (+237%) by 2050 · US Dollar
Based on the average projected CVM price of $4.75 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CVMwould be worth at today's price.
$1,000 invested in CVM on May 27, 2025 (≈ 398.406376 CVM) would be worth
$561.75
-$438.25 (-43.8%) today · 0.56× · US Dollar
Based on a CVM entry price of $2.51 vs. today's $1.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.59 | $886.79 | -11.3% |
| 1 month ago | $3.26 | $432.52 | -56.7% |
| 3 months ago | $4.56 | $309.21 | -69.1% |
| 6 months ago | $7.67 | $183.83 | -81.6% |
| 1 year ago | $2.51 | $561.75 | -43.8% |
| All time (5.0y) ago | $656.7 | $2.15 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CVM forecast.
Our base-case forecast reaches $2.80 around 2040.
Implied market cap at $2.80: $40.58M
The multi-year forecast shows a gradual upward path in average price from 2026 through the 2030s and into 2050. The 2026 average is $1.42, rising to $1.87 in 2027 and $1.99 in 2028, with a 2029 average of $1.74 and a 2030 average of $1.53 (ROIs 0, 31.8, 40, 22.3, and 7.9 respectively). The sentiment for 2027–2029 is BULLISH, turning neutral in 2030–2031 before returning to BULLISH in 2032–2035 and continuing to be BULLISH through 2040 and 2050.
Longer-horizon forecasts show stronger upside: the 2040 average is $3.01 with ROI 111.6, and the 2050 average is $4.80 with ROI 237.9. The max forecast price reaches $6.61 in 2040 and $11.03 in 2050, illustrating the potential upside under optimistic scenarios while still reflecting substantial uncertainty and risk.
These numbers represent estimates and are not guarantees. The path to higher prices is subject to market dynamics and the company’s clinical and regulatory developments, among other factors.
Tap a question to reveal the answer.
2030 average price is $1.53 with a min of $0.941 and a max of $2.67, and an ROI of 7.9. The sentiment is NEUTRAL.
The current price is $1.42 with a forecast that includes neutral in 2026 and bullish periods in 2027–2029 and 2032–2035, plus strong bullish outlook in 2040 and 2050. The 2030 figure shows an average of $1.53 and ROI of 7.9, while the 2050 max is $11.03 and the 2050 average is $4.80 with ROI 237.9. These are estimates and not guarantees.
According to the forecast, the 2040 max is $6.61 and the 2050 max is $11.03, with the 2050 average at $4.80. A price of $5 is within the forecasted max range, but not guaranteed.
The 30-day price range runs from $0.7893 to $2.55, and the annualized volatility is 200%, indicating a high level of volatility.
The current price is $1.42, the market capitalization is $20.58M, and the rank is 4930.
CEL-SCI Corporation Community Discussion
0Share your CEL-SCI Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.